chronic pancreatitis
Progressive fibrosis → pain, exocrine insufficiency (steatorrhoea, weight loss), diabetes. Diagnose with CT or MRI (calcifications, duct dilatation, atrophy); EUS or secretin-MRCP only if imaging is equivocal. Find the cause (TIGAR-O; genetics if young or unexplained). Stop alcohol and smoking. PERT treats malabsorption, not pain. Pain: non-opioid analgesia → endoscopic drainage of obstructed ducts → surgery if that fails. Autoimmune pancreatitis mimics cancer and responds to steroids.
diagnosis
- CT or MRI first; EUS (invasive, non-specific) only if cross-sectional imaging is equivocal. Secretin-enhanced MRCP when suspicion stays high.
- Histology is the gold standard but rarely needed.
- Pancreatic function tests (faecal elastase) diagnose exocrine insufficiency, not chronic pancreatitis itself.
- Lipase is often normal — burnt-out gland.
aetiology (TIGAR-O)
| examples | |
|---|---|
| Toxic-metabolic | alcohol, smoking (independent, synergistic), hypercalcaemia, hypertriglyceridaemia, CKD |
| Idiopathic | early and late onset |
| Genetic | PRSS1, SPINK1, CFTR, CTRC → test if young or unexplained |
| Autoimmune | type 1 (IgG4-related) and type 2 AIP |
| Recurrent acute | recurrent acute pancreatitis progressing to fibrosis |
| Obstructive | pancreas divisum, ampullary stenosis, tumour, post-necrotic stricture |
Age >40 with new unexplained pancreatitis → exclude pancreatic cancer.
management
Remove the cause — alcohol and smoking cessation slow progression and reduce pain. Postpone elective procedures while drinking.
exocrine insufficiency
- Steatorrhoea, weight loss, fat-soluble vitamin deficiency; faecal elastase low (<200 µg/g).
- PERT with meals — e.g. ~40 000–50 000 lipase units with meals, half with snacks; add a PPI if response is poor.
- Monitor nutrition: weight, vitamins A, D, E, K, and DEXA (osteoporosis common).
pain
- Analgesia (acetaminophen, NSAID, tramadol); opioids only after other options fail.
- Antioxidants: small benefit.
- PERT doesn’t relieve pain.
- Obstructed main duct (stones, stricture) → endoscopic therapy (ERCP ± lithotripsy).
- Endoscopy fails or pain recurs → surgery (drainage or resection) — better long-term pain relief than repeated endoscopy.
- Coeliac plexus block for selected patients; total pancreatectomy with islet autotransplantation only for highly selected refractory pain.
complications
- Diabetes (type 3c) — loss of insulin and glucagon → brittle, hypoglycaemia-prone; screen periodically (HbA1c, fasting glucose).
- Pseudocyst (vs cystic neoplasm → pancreatic cysts and familial pancreatic cancer surveillance), bile duct or duodenal stricture, splenic vein thrombosis (→ isolated gastric varices).
- Pancreatic cancer risk is raised, but routine screening hasn’t shown benefit.
autoimmune pancreatitis
| type 1 | type 2 | |
|---|---|---|
| disease | pancreatic part of IgG4-related disease | duct-centric, granulocytic epithelial lesions |
| who | older men | younger, either sex |
| serum IgG4 | often raised | normal |
| other organs | biliary (IgG4 cholangitis), salivary, kidney, retroperitoneum | IBD (UC) |
| relapse | common (~30%) | rare (~10%) |
- Presents as painless obstructive jaundice, a “sausage-shaped” pancreas or a focal mass → pancreatic cancer must be excluded first (EUS-guided biopsy); a steroid trial is not a diagnostic shortcut unless cancer has been ruled out.
- IgG4 cholangitis mimics PSC and cholangiocarcinoma → check IgG4 in sclerosing cholangitis (primary biliary and sclerosing cholangitis).
- Serum IgG4 is the single best serological marker (>2× ULN strongly suggestive with jaundice or a mass), but normal in type 2.
- Prednisone 0.6–1 mg/kg/day, reassess imaging and CA 19-9 at 2 weeks, taper over ~12 weeks total (not <4). Type 1 may need low-dose maintenance (2.5–7.5 mg/day up to 3 years) or a steroid-sparing agent; type 2 usually doesn’t. Mild jaundice without infection → steroids alone, stenting not required.
- Steroids induce remission in almost all; rituximab if steroids are contraindicated or for relapse. Thiopurines alone don’t induce remission.
- Treat symptomatic disease (jaundice, pain, other-organ involvement) or subclinical disease threatening irreversible damage.
Prepared 2026-10-28. Not yet verified — check every number against the sources.